Qiagen Q4 Earnings Call Highlights

Qiagen logo Key Points Qiagen beat its outlook for 2025, reporting full-year net sales of $2.09 billion (+5% CER) and adjusted EPS of$ 2.40, with Q4 net sales of $540 million (+1% CER) and adjusted EPS of$ 0.62. The company’s five “growth pillars” generated $1.49 billion in 2025 (up 8% CER) — led by QIAstat‑Dx, QuantiFERON, QIAcuity, Sample Technologies and QDI — and management says this keeps Qiagen on track for at least$ 2 billion of combined growth‑pillar sales by 2028, aided by the Parse Bioscienc ...